THERAPEUTIC RESEARCH IN ACCELERATED DISCOVERY (TRIAD) PROGRAM REQUEST FOR PROPOSAL GUIDELINES
The TRIAD Program from the Hereditary Neuropathy Foundation funds innovative, milestone-driven preclinical research to accelerate new therapies for hereditary neuropathies.
Funder: Hereditary Neuropathy Foundation
Due Dates: Rolling (no deadline)
Funding Amounts: $50,000–$100,000 per year (direct costs); 1-year projects, possible 12-month extension; higher budgets considered for exceptional proposals
Summary: Supports milestone-driven, preclinical research in therapeutic discovery for hereditary neuropathies, emphasizing collaboration and rapid translation.
Key Information: Indirect costs are not allowed; reach out to HNF before submitting a Letter of Intent.
Description
The Therapeutic Research in Accelerated Discovery (TRIAD) program, offered by the Hereditary Neuropathy Foundation, is designed to accelerate preclinical research that advances therapeutic discovery for hereditary neuropathies, including Charcot-Marie-Tooth disease (CMT). The program emphasizes collaborative project development, encouraging open dialogue between researchers, clinicians, industry partners, and the foundation prior to submission. Projects should be innovative, milestone-driven, and aligned with HNF’s mission to rapidly translate scientific findings into patient benefit.
The TRIAD program funds research globally and prioritizes projects with clear milestones and measurable outcomes. It also welcomes multi-year proposals if justified by research progress and milestones achieved. The TRIAD Council, consisting of thought leaders and experts in the field, reviews proposals and guides the research strategy to maximize impact.
